Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Rolul preparatului BioR în tratamentul complex (adjuvant) al adenomului de prostată

Show simple item record

dc.contributor.author Ceban, Emil
dc.contributor.author Banov, Pavel
dc.contributor.author Galescu, Andrei
dc.contributor.author Tănase, Adrian
dc.contributor.author Rudic, Valeriu
dc.contributor.author Guţu, Constantin
dc.date.accessioned 2020-05-02T08:53:48Z
dc.date.available 2020-05-02T08:53:48Z
dc.date.issued 2011
dc.identifier.citation CEBAN, E., BANOV, P., GALESCU, A., et.al. Rolul preparatului BioR în tratamentul complex (adjuvant) al adenomului de prostată. In: Arta Medica. 2011, nr. 2(45), pp. 14-19. ISSN 1810-1852. en_US
dc.identifier.issn 1810-1852
dc.identifier.issn 1810-1852
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/9002
dc.description Catedra Urologie şi Nefrologie Chirurgicală USMF „N. Testemiţanu”, Catedra Microbiologie, Virusologie şi Imunologie USMF „N. Testemiţanu”, Al V-lea Congres de Urologie, Dializă şi Transplant Renal din Republica Moldova cu participare internaţională (1-13 iunie 2011) en_US
dc.description.abstract Summary. The aim of the study was to determine the efficiency of BioR medication in patients with benign prostatic hyperplasia (BPH) by monitoring serum PSA and testosterone levels, prostate volume, residual urine and International Prostate Symptom Score (IPSS) and quality of life index(QoL). The study was performed on a group of 44 male patients. Inclusion criteria in the study were: men with confirmed diagnosed BPH in outpatient treatment, patients with symptomatic obstructive and irritable symptoms and patients who agreed to this treatment with additional agreement confirmed by signature. The patients who were included in this study were divided in two groups: 24 patients in the basic group and 20 patients in the control group. Treatment administered to the main group of patients was BioR. Patients were monitored for 90 days with three visits to the doctor. Results of this dynamic study were assessed. All exposed indicators were analyzed statistically using Student test. Serum testosterone levels in study group I increased in average from 3.5 (first visit) to 4.43 (second visit) and evolved through growth figures up to the 6.85 average at the end of treatment. PSA indicators showed that statistically significant differences from the control group were constant throughout the study. In group I patients score values of IPSS and QoL decreased significantly at visit 2 and 3. With regard to prostate volume, during the evaluation we found a statistical difference only during the 3rd visit. In both indicated groups there was a decrease of residual urine dynamics, the most significant being with the incapacitated patients from the main group. Based on this study, by statistical confirmation, it can be concluded that BioR is efficient medication in patients with early stage of grade one and two benign prostatic hyperplasia. Drug action to normalize serum levels of PSA and testosterone was also found. There were established effects of improving IPSS score and QoL index. en_US
dc.language.iso ro en_US
dc.publisher Asociaţia chirurgilor “Nicolae Anestiadi” din Republica Moldova en_US
dc.subject.mesh Prostatic hyperplasia--drug therapy en_US
dc.subject.mesh BioR--therapeutic use en_US
dc.title Rolul preparatului BioR în tratamentul complex (adjuvant) al adenomului de prostată ro
dc.title.alternative Role of medication BioR in complex treatment of benign prostatic hyperplasia en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics